084650.Kq
The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
Business. The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidity is assessed as medium, with negative net cash after subtracting total debt, suggesting potential short-term liquidity constraints. The price-to-book ratio of 0.65 and the price-to-tangible-book ratio of 0.65 indicate that the company's market value is trading at a discount to its book value, which may reflect market concerns about its financial health or future earnings potential.
Profitability metrics show a return on equity of -0.4302 and a return on assets of -0.2797, both of which are significantly below the industry median and indicate a loss-making position. The company's operating income and net income are negative, at -59.89 billion KRW and -64.37 billion KRW, respectively, which further underscores the poor financial performance. These figures suggest that the company is not generating sufficient revenue to cover its operating costs and is experiencing a decline in profitability.
The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification may expose the company to higher risks if market conditions in its primary segment or region deteriorate. The absence of detailed segment and geographic data limits the ability to assess the company's exposure to different markets and potential for growth.
The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year indicates a continuation of this trend, with no positive revenue growth expected. The company's operating cash flow is negative at -30.54 billion KRW, and its free cash flow is also negative at -55.73 billion KRW, which suggests that the company is not generating enough cash to sustain operations or fund growth initiatives. The capital expenditure of -1.66 billion KRW indicates a reduction in investment in long-term assets, which may affect future growth potential.
The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's negative operating and net income, along with its negative cash flows, may necessitate future financing activities that could lead to dilution. The company's financial performance and liquidity position suggest that it may need to seek additional capital, which could involve issuing new shares or taking on more debt.
Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The financial snapshot indicates a challenging operating environment, with the company reporting significant losses and negative cash flows. The absence of recent events or transcripts limits the ability to assess the company's response to these challenges or its plans for improvement.
- The company is currently experiencing significant financial losses, with negative operating and net income.
- The company's liquidity position is medium, with negative net cash after subtracting total debt.
- The company's profitability metrics are well below the industry median, indicating poor financial performance.
- The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.37.
- The company's growth trajectory is negative, with no positive revenue growth expected in the current fiscal year.
- The company's market value is trading at a discount to its book value, which may reflect market concerns about its financial health.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 084650.KQ Market data — financials · 2026-05-26